281 related articles for article (PubMed ID: 15171905)
1. [Abnormal body fat distribution and type of antiretroviral therapy as predictors of cardiovascular disease risk in HIV-infected patients].
Ena J; Benito C; Llácer P; Pasquau F; Amador C
Med Clin (Barc); 2004 May; 122(19):721-6. PubMed ID: 15171905
[TBL] [Abstract][Full Text] [Related]
2. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
[TBL] [Abstract][Full Text] [Related]
3. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens.
Taylor P; Worrell C; Steinberg SM; Hazra R; Jankelevich S; Wood LV; Zwerski S; Yarchoan R; Zeichner S
Pediatrics; 2004 Aug; 114(2):e235-42. PubMed ID: 15286262
[TBL] [Abstract][Full Text] [Related]
4. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
[TBL] [Abstract][Full Text] [Related]
5. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART).
Dong KL; Bausserman LL; Flynn MM; Dickinson BP; Flanigan TP; Mileno MD; Tashima KT; Carpenter CC
J Acquir Immune Defic Syndr; 1999 Jun; 21(2):107-13. PubMed ID: 10360801
[TBL] [Abstract][Full Text] [Related]
6. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
7. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.
Mercier S; Gueye NF; Cournil A; Fontbonne A; Copin N; Ndiaye I; Dupuy AM; Cames C; Sow PS; Ndoye I; Delaporte E; Simondon KB
J Acquir Immune Defic Syndr; 2009 Jun; 51(2):224-30. PubMed ID: 19339897
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
9. Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection.
Tanwani LK; Mokshagundam SL
South Med J; 2003 Feb; 96(2):180-8; quiz 189. PubMed ID: 12630645
[TBL] [Abstract][Full Text] [Related]
10. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors.
Martínez E; Domingo P; Ribera E; Milinkovic A; Arroyo JA; Conget I; Pérez-Cuevas JB; Casamitjana R; de Lazzari E; Bianchi L; Montserrat E; Roca M; Burgos R; Arnaiz JA; Gatell JM
Antivir Ther; 2003 Oct; 8(5):403-10. PubMed ID: 14640387
[TBL] [Abstract][Full Text] [Related]
11. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
[TBL] [Abstract][Full Text] [Related]
12. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy.
Gervasoni C; Ridolfo AL; Trifirò G; Santambrogio S; Norbiato G; Musicco M; Clerici M; Galli M; Moroni M
AIDS; 1999 Mar; 13(4):465-71. PubMed ID: 10197374
[TBL] [Abstract][Full Text] [Related]
13. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
[TBL] [Abstract][Full Text] [Related]
14. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A
AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852
[TBL] [Abstract][Full Text] [Related]
15. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome.
Kosmiski LA; Kuritzkes DR; Lichtenstein KA; Glueck DH; Gourley PJ; Stamm ER; Scherzinger AL; Eckel RH
AIDS; 2001 Oct; 15(15):1993-2000. PubMed ID: 11600828
[TBL] [Abstract][Full Text] [Related]
16. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy.
Koppel K; Bratt G; Schulman S; Bylund H; Sandström E
J Acquir Immune Defic Syndr; 2002 Apr; 29(5):441-9. PubMed ID: 11981359
[TBL] [Abstract][Full Text] [Related]
17. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.
Saint-Marc T; Partisani M; Poizot-Martin I; Rouviere O; Bruno F; Avellaneda R; Lang JM; Gastaut JA; Touraine JL
AIDS; 2000 Jan; 14(1):37-49. PubMed ID: 10714566
[TBL] [Abstract][Full Text] [Related]
18. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy.
Vigouroux C; Maachi M; Nguyên TH; Coussieu C; Gharakhanian S; Funahashi T; Matsuzawa Y; Shimomura I; Rozenbaum W; Capeau J; Bastard JP
AIDS; 2003 Jul; 17(10):1503-11. PubMed ID: 12824788
[TBL] [Abstract][Full Text] [Related]
19. COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort.
Mayanja BN; Kasamba I; Levin J; Namakoola I; Kazooba P; Were J; Kaleebu P; Munderi P;
AIDS Res Ther; 2017; 14():26. PubMed ID: 28484508
[TBL] [Abstract][Full Text] [Related]
20. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations.
Christeff N; Melchior JC; de Truchis P; Perronne C; Nunez EA; Gougeon ML
AIDS; 1999 Nov; 13(16):2251-60. PubMed ID: 10563710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
